Trials / Withdrawn
WithdrawnNCT04395118
STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs
STOP-HCC Evidence-Based Hepatocellular Cancer Prevention Through Treatment of Hepatitis C Virus Infection
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The investigators will conduct a randomized controlled trial comparing two strategies to promote HCV screening, follow-up testing, and treatment among Parkland patients who are 18 years or older who have elevated liver functioning test (LFT) results: in reach with electronic medical record alerts and provider education vs. combination of in reach and provider education plus mailed outreach and patient navigation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Mailed Outreach | The investigators will randomize elevated LFT patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2). |
Timeline
- Start date
- 2020-08-15
- Primary completion
- 2021-06-01
- Completion
- 2022-01-01
- First posted
- 2020-05-20
- Last updated
- 2020-07-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04395118. Inclusion in this directory is not an endorsement.